Biotech Values

[DewDiligence]

I question the premise of this Reportlinker research report on FoB’s:

http://finance.yahoo.com/news/biosimilars-emerging-economies-advanced-recombinant-105800680.html

Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production

Probably true for FoB’s that are non-interchangeable with their branded counterparts. For interchangeable FoB’s, on the other hand, rock-bottom manufacturing cost would seem to be less important than the ease of establishing sameness to the FDA’s satisfaction.

p.s. Teva’s low-cost effort at producing generic Lovenox hasn’t worked out well.